TRUPCR Europe Ltd and its parent company, 3B BlackBio Dx Ltd, announce they have completed the acquisition of Coris BioConcept, strengthening its position in global diagnostics.
Based in Gembloux, Belgium, Coris is a recognized innovator in CE‑IVD rapid lateral flow test kits for respiratory, gastro‑enteric, blood‑borne pathogens and antibiotic resistance markers. Built on a foundation of ISO 13485 quality and a newly commissioned modern facility, Coris’s portfolio is a perfect complement to TRUPCRs PCR‑based assays
This acquisition aligns with the companies vision to deliver a full-spectrum in‑vitro diagnostics range, combining TRUPCR®’s highly sensitive PCR diagnostics and Coris’s rapid tests to support healthcare professionals globally.
The acquisition means:
📈 Expanded diagnostics capabilities, from centralized labs to decentralized settings
🌍 Broader global reach across Europe, Asia, Africa, and beyond
💡 Enhanced IP‑rich product development across both PCR and lateral flow technologies
The Company is excited about the next chapter in its growth journey and are delighted to welcome the Coris team.
